Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)

Document first published:
Page updated:
Topic:
,
Publication type:

Following further data from the immune modulation therapy domain of the REMAP-CAP, an updated UK-wide Interim Position Statement has been agreed to support the off-label prescribing and access to tocilizumab or sarilumab, administered intravenously, for eligible COVID-19 positive patients in the intensive care setting.